Pancreatic Cancer Research

Clinical trialPhase 1Completed

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

A Phase I, Open-Label, Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Infused SNB-101(as SN-38) in Patients With Advanced Solid Tumors

Outcome
Finished, no results posted
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
21 October 2020
Ended
5 January 2026
Enrollment
21 participants
Sites
3
Primary outcomes
Dose-limiting toxicity(DLT); Permanent discontinuation of SNB-101 and dose reduction due to adverse events(AEs); Number of participants with clinically meaningful changes in Laboratory test results from baseline; Number of participants with clinically meaningful changes in Vital signs from baseline; Electrocardiogram(ECG) results
Sponsor type
Industry
Results posted
No
Last update
27 January 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in participants with advanced solid tumors. Dose escalation will occur using a modified accelerated titration design (ATD). All participants will receive SNB 101 in different cohorts. SNB 101 will be administered intravenously to participants on day 1 and day 15 of each 28 day treatment cycle until progressive disease, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. A Safety Review Committee will determine dose escalation, de-escalation, and modification and the MTD/RP2D based on DLTs and other safety information.

Detailed description public domain (ClinicalTrials.gov)

Each participant will undergo a screening period, a treatment period, and a follow-up period. Participants will be followed until death, withdrawal of consent, or end of study, whichever occurs first. During the treatment period, participants will receive SNB-101 (dose range: 5 mg/m2 to 50 mg/m2) intravenously on day 1 and day 15 of each 28 day cycle. Dose reductions are permitted after the DLT observation period, which occurs during the first 28 days of treatment (cycle 1). Participants may permanently or temporarily (at the investigator's discretion) discontinue SNB-101. If a participant experiences a DLT or unacceptable toxicity, SNB-101 treatment should be interrupted until the observed toxicity returns to baseline or ≤ grade 1 toxicity. The start of the next cycle can be delayed up to 2 weeks at the investigator's discretion.

Intervention public domain (ClinicalTrials.gov)

Drug: SNB-101. SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting

Arm public domain (ClinicalTrials.gov)

Cohort 1 (experimental): SNB-101 5/8mg/m2 Q2W IV

Arm public domain (ClinicalTrials.gov)

Cohort 2 (experimental): SNB-101 10/16mg/m2 Q2W IV

Arm public domain (ClinicalTrials.gov)

Cohort 3 (experimental): SNB-101 20/32mg/m2 Q2W IV

Arm public domain (ClinicalTrials.gov)

Cohort 4 (experimental): SNB-101 30/48mg/m2 Q2W IV

Arm public domain (ClinicalTrials.gov)

Cohort 5 (experimental): SNB-101 40/64mg/m2 Q2W IV

Arm public domain (ClinicalTrials.gov)

Cohort 6 (experimental): SNB-101 45/72mg/m2 Q2W IV

Primary outcome public domain (ClinicalTrials.gov)

Dose-limiting toxicity(DLT). * All participants who take at least 1 dose of SNB-101 will be assessed. * DLTs will be presented by dose group and the MTD determined. \*DLTs : 1\) Hematological toxicity * Grade 4 thrombocytopenia * Grade 3 thrombocytopenia with clinically significant bleeding * Grade 4 neutropenia lasting \> 7 days * ≥ grade 3 febrile neutropenia 2\) Nonhematological toxicity * Any ≥ grade 3 nonhematological toxicity 3\) Liver function abnormalities * Patients who have bone or liver metastasis with the following increases will be considered a DLT: 1. Baseline AST or ALT = 2.5 to 5× ULN, then AST or ALT that increases to \>8× ULN 2. Baseline ALP = 2.5 to 5×ULN, then ALP increases to \>8×ULN 4\) Any toxicity related to SNB-101 that results in a treatment delay of more than 2 weeks. Time frame: up to 18 months(depending on safety variable).

Primary outcome public domain (ClinicalTrials.gov)

Permanent discontinuation of SNB-101 and dose reduction due to adverse events(AEs). Definition of permanent discontinuation of SNB-101: 1. Experiencing a DLT or intolerable toxicity during the DLT observation period. 2. Experiencing life-threatening Grade 4 adverse events (AE). 3. Experiencing Grade 2 interstitial lung disease or Grade 4 infusion related reaction/ hypersensitivity. * Descriptive statistics for continuous variables, frequency and percentage for categorical variables Time frame: up to 18 months(depending on safety variable).

Primary outcome public domain (ClinicalTrials.gov)

Number of participants with clinically meaningful changes in Laboratory test results from baseline. * Hematology: RBC count, WBC count, hemoglobin, hematocrit, platelets, mean cell volume, mean cell hemoglobin, mean cell hemoglobin concentration, WBC differential count, ANC. * Serum biochemistry: BUN, creatinine, glucose (random), aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, total protein, albumin, Ca, P, K, Na, Cl, CO2, GGT, and LDH. * Coagulation: prothrombin time and international normalized ratio. * Viral serology: viral serology test for HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus antibody. The test can be waived for participants who have results within 28 days prior to screening. * Urinalysis: specific gravity, protein, pH, blood, and ketones. * Descriptive statistics for continuous variables, frequency and percentage for categorical variables Time frame: up to 18 months(depending on safety variable).

Primary outcome public domain (ClinicalTrials.gov)

Number of participants with clinically meaningful changes in Vital signs from baseline. * Vital signs include blood pressure(sitSBP/sitDBP), heart rate, respiratory rate, and body temperature. Change from baseline or previous visit will be described. * After each infusion of SNB-101, vital signs will be monitored every 30 minutes for 3 hours on an outpatient basis. * Descriptive statistics for continuous variables, frequency and percentage for categorical variables Time frame: up to 18 months(depending on safety variable).

Primary outcome public domain (ClinicalTrials.gov)

Electrocardiogram(ECG) results. * ECG data will be collected at screening, C1D1, C3D1 and EOT. * ECG measurement at C1D1 and C3D1 will be performed after PK sampling at the end of the infusion (90 min.), 2.5 hours and 24 hours after drug administration. * ECG QT interval will be assessed for the safety endpoint(e.g. QTc prolongation) * Descriptive statistics for continuous variables, frequency and percentage for categorical variables Time frame: up to 18 months(depending on safety variable).

Secondary outcome public domain (ClinicalTrials.gov)

Area under the plasma concentration-time curve(AUC). Time frame: 4 months.

Secondary outcome public domain (ClinicalTrials.gov)

Maximum plasma concentration(Cmax). Time frame: 4 months.

Secondary outcome public domain (ClinicalTrials.gov)

Time to Cmax(Tmax). Time frame: 4 months.

Secondary outcome public domain (ClinicalTrials.gov)

Clearance(CL). Time frame: 4 months.

Secondary outcome public domain (ClinicalTrials.gov)

Volume of distribution(Vd). Time frame: 4 months.

Secondary outcome public domain (ClinicalTrials.gov)

Terminal half-life(t1/2). Time frame: 4 months.

Eligibility public domain (ClinicalTrials.gov)

Inclusion Criteria: * Patients with a histologically or cytologically confirmed, locally advanced or metastatic disease, has progressed after systemic standard of care treatment for advanced disease and is not suitable for complete surgical resection. * Patients with measurable or evaluable disease consistent with Response Evaluation Criteria in Solid Tumors version 1.1. * Patients ambulatory with an Eastern Cooperative Oncology Group performance score of 0 or 1. * Patients with adequate hematological, renal, and liver function(CTCAE V5.0 grade 1 or lower). * Patients with the life expectancy of 3 months or longer. Exclusion Criteria: * Patients homozygous for UGT1A1\*28 or UGT1A1\*6 alleles. * Patients known or suspected intolerance or hypersensitivity to main ingredient or any of the excipients of SNB-101. * Patients with unintentional weight loss \>10% within 3 months prior to screening. * Patients who are on dialysis. * Patients who are positive for HIVs. * Patients with a QT interval with Fridericia's correction outside of normal. * Patients with intestinal palsy or bowel obstruction. * Patients with chronic inflammatory bowel disease. * Patients who may require administration of neuromuscular blockers, peripheral muscle relaxants, etc. during the study. * Patients who may require lapatinib during the study. * Patients who may require attenuated vaccine during the study. * Patients who are taking any medication that in the judgement of the investigator could have an effect on the action of SNB-101. * Patients unable to participate in the study as judged by the investigator.

Enrollment public domain (ClinicalTrials.gov)

Enrollment: 21 participants (actual).